• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨噬细胞在血管内皮生长因子受体-3 特异性配体诱导的血管生成中的作用。

Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.

机构信息

Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Am J Pathol. 2009 Nov;175(5):1984-92. doi: 10.2353/ajpath.2009.080515. Epub 2009 Oct 1.

DOI:10.2353/ajpath.2009.080515
PMID:19808642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2774062/
Abstract

Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.

摘要

血管内皮生长因子受体 (VEGFR)-2 是促血管生成 (HA) 的主要刺激物,而 VEGFR-3 则刺激淋巴管生成 (LA)。与这种理解相反,我们证明将含有 VEGFR-3 特异性配体(VEGF-C156S 和重组鼠 VEGF-D)的小丸植入角膜基质中不仅会诱导 LA,还会诱导具有特征性的血管生成,这些血管对 VEGFR-3 表达呈阳性。植入含有 VEGFR-3 特异性配体的小丸还会导致分泌 VEGF-A 的巨噬细胞的募集。使用氯膦酸盐脂质体给药耗尽这些浸润的巨噬细胞会导致 HA 和 LA 明显减少。阻断 VEGFR-2 或 VEGFR-3 信号均可减少 HA 和 LA,但 VEGFR-2 阻断组中 HA 的减少百分比更大。此外,在 VEGFR-3 阻断组中,VEGFR-3 特异性配体引起的 HA 减少百分比明显大于 VEGF-A 或 VEGF-C。总之,我们的数据表明,VEGFR-3 特异性信号可以诱导新的血管,巨噬细胞在其中发挥主要作用,并表明其作为现有基于 VEGF-A/VEGFR-2 信号的抗血管生成策略的附加治疗靶点的潜力。

相似文献

1
Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.巨噬细胞在血管内皮生长因子受体-3 特异性配体诱导的血管生成中的作用。
Am J Pathol. 2009 Nov;175(5):1984-92. doi: 10.2353/ajpath.2009.080515. Epub 2009 Oct 1.
2
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.酪氨酸激酶抑制剂西地尼布可阻断配体诱导的血管内皮生长因子受体-3活性及淋巴管生成。
Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.
3
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.淋巴管生成生长因子血管内皮生长因子(VEGF)-C和-D的差异受体结合及调控机制
J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16.
4
Differential expression of VEGF ligands and receptors in prostate cancer.血管内皮生长因子配体和受体在前列腺癌中的差异表达。
Prostate. 2013 May;73(6):563-72. doi: 10.1002/pros.22596. Epub 2012 Oct 4.
5
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.可溶性血管内皮生长因子受体-3 抑制膀胱癌中的淋巴管生成和淋巴转移。
Mol Cancer. 2011 Apr 11;10:36. doi: 10.1186/1476-4598-10-36.
6
Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.神经母细胞瘤的进展与淋巴管生成抑制剂 sVEGFR-2 的下调相关。
Clin Cancer Res. 2010 Mar 1;16(5):1431-41. doi: 10.1158/1078-0432.CCR-09-1936. Epub 2010 Feb 23.
7
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.VEGFR-3 通过增强 Notch 信号控制血管融合部位的尖端到干转换。
Nat Cell Biol. 2011 Sep 11;13(10):1202-13. doi: 10.1038/ncb2331.
8
Molecular control of lymphatic metastasis.淋巴转移的分子调控
Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020.
9
Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.血管内皮生长因子-D 受体结合和特异性的结构决定因素。
Blood. 2011 Feb 3;117(5):1507-15. doi: 10.1182/blood-2010-08-301549. Epub 2010 Dec 8.
10
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.前列腺癌中血管内皮生长因子轴的阶段特异性特征:淋巴管生成标志物的表达与晚期疾病相关。
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93.

引用本文的文献

1
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3CD11b cells.玻璃体内注射阿柏西普抑制角膜血管生成和 VEGFR-3CD11b 细胞。
Graefes Arch Clin Exp Ophthalmol. 2024 Dec;262(12):3881-3888. doi: 10.1007/s00417-024-06560-4. Epub 2024 Jul 9.
2
Essential role of M1 macrophages in blocking cytokine storm and pathology associated with murine HSV-1 infection.M1 巨噬细胞在阻断细胞因子风暴和与小鼠 HSV-1 感染相关的病理学中的重要作用。
PLoS Pathog. 2021 Oct 15;17(10):e1009999. doi: 10.1371/journal.ppat.1009999. eCollection 2021 Oct.
3
Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series.局部应用贝伐单抗治疗犬角膜血管化:病例系列研究。
Vet Ophthalmol. 2021 Sep;24(5):554-568. doi: 10.1111/vop.12931. Epub 2021 Sep 6.
4
Macrophage-Mediated Tissue Vascularization: Similarities and Differences Between Cornea and Skin.巨噬细胞介导的组织血管生成:角膜与皮肤的相似与不同。
Front Immunol. 2021 Apr 7;12:667830. doi: 10.3389/fimmu.2021.667830. eCollection 2021.
5
Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.肿瘤相关巨噬细胞、血管生成和淋巴管生成标志物预测非小细胞肺癌患者的预后。
J Transl Med. 2020 Nov 23;18(1):443. doi: 10.1186/s12967-020-02618-z.
6
Potential functions of embryonic cardiac macrophages in angiogenesis, lymphangiogenesis and extracellular matrix remodeling.胚胎心脏巨噬细胞在血管生成、淋巴管生成和细胞外基质重塑中的潜在功能。
Histochem Cell Biol. 2021 Jan;155(1):117-132. doi: 10.1007/s00418-020-01934-1. Epub 2020 Nov 1.
7
Role of macrophages in fetal development and perinatal disorders.巨噬细胞在胎儿发育和围产期疾病中的作用。
Pediatr Res. 2021 Sep;90(3):513-523. doi: 10.1038/s41390-020-01209-4. Epub 2020 Oct 18.
8
Lipid Keratopathy: A Review of Pathophysiology, Differential Diagnosis, and Management.脂质角膜病变:病理生理学、鉴别诊断及治疗综述
Ophthalmol Ther. 2020 Dec;9(4):833-852. doi: 10.1007/s40123-020-00309-y. Epub 2020 Oct 15.
9
Inflammation suppression prevents tumor cell proliferation in a mouse model of thyroid cancer.在甲状腺癌小鼠模型中,炎症抑制可防止肿瘤细胞增殖。
Am J Cancer Res. 2020 Jun 1;10(6):1857-1870. eCollection 2020.
10
Topical VEGF-C/D Inhibition Prevents Lymphatic Vessel Ingrowth into Cornea but Does Not Improve Corneal Graft Survival.局部抑制血管内皮生长因子C/D可防止淋巴管长入角膜,但不能提高角膜移植存活率。
J Clin Med. 2020 Apr 28;9(5):1270. doi: 10.3390/jcm9051270.

本文引用的文献

1
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.阻断血管内皮生长因子受体-3可抑制血管生成芽生和血管网络形成。
Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.
2
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.血管内皮生长因子受体2介导巨噬细胞浸润小鼠原位胰腺肿瘤。
Cancer Res. 2008 Jun 1;68(11):4340-6. doi: 10.1158/0008-5472.CAN-07-6705.
3
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.血管内皮生长因子受体3参与肿瘤血管生成和生长。
Cancer Res. 2007 Jan 15;67(2):593-9. doi: 10.1158/0008-5472.CAN-06-3567.
4
Priming by tumor necrosis factor-alpha of human neutrophil NADPH-oxidase activity induced by anti-proteinase-3 or anti-myeloperoxidase antibodies.肿瘤坏死因子-α对蛋白酶3抗体或髓过氧化物酶抗体诱导的人中性粒细胞NADPH氧化酶活性的启动作用。
J Leukoc Biol. 2006 Dec;80(6):1424-33. doi: 10.1189/jlb.0304144. Epub 2006 Sep 22.
5
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.与使VEGFR-2失活相比,用拮抗抗体抑制VEGFR-3激活能更有效地抑制淋巴结转移和远处转移。
Cancer Res. 2006 Mar 1;66(5):2650-7. doi: 10.1158/0008-5472.CAN-05-1843.
6
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.血管内皮生长因子受体在血管生成和淋巴管生成调控中的信号转导
Exp Cell Res. 2006 Mar 10;312(5):549-60. doi: 10.1016/j.yexcr.2005.11.012. Epub 2005 Dec 5.
7
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.一种新型VEGFR-3中和抗体对成年淋巴管再生的完全且特异性抑制。
J Natl Cancer Inst. 2005 Jan 5;97(1):14-21. doi: 10.1093/jnci/dji003.
8
Lymphatic regeneration: new insights from VEGFR-3 blockade.淋巴再生:VEGFR-3阻断的新见解
J Natl Cancer Inst. 2005 Jan 5;97(1):2-3. doi: 10.1093/jnci/dji015.
9
The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.血管内皮生长因子(VEGF)/VEGF受体2通路对于啮齿动物孕期黄体中的血管存活至关重要。
Endocrinology. 2005 Mar;146(3):1301-11. doi: 10.1210/en.2004-0765. Epub 2004 Dec 9.
10
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva.结膜中单核细胞来源的骨髓细胞上血管内皮生长因子受体-3(VEGFR-3)的表达。
Exp Eye Res. 2004 Oct;79(4):553-61. doi: 10.1016/j.exer.2004.06.028.